Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECI-006
- Development stage
- Unknown
- Lead developer
- eTheRNA immunotherapies
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intranodal
01
Overview
ECI-006 is an investigational mRNA-based cancer vaccine developed for the treatment of melanoma. It consists of a combination of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and utilizes the TriMix platform, which includes three mRNAs encoding constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70. This design aims to optimally activate dendritic cells, thereby stimulating a robust T-cell-mediated immune response against melanoma cells. The vaccine is administered via intranodal injection and has been evaluated both as monotherapy after tumor resection and in combination with anti-PD1 therapy in patients with metastatic melanoma. Clinical trials have demonstrated measurable immune responses against tumor antigens, though development appears to have been discontinued at phase 1[1][2][3][7][8].
- Other names
- TriMix MELmRNA-based TriMixMelanoma vaccine
02
Targets
CD27 (Cluster of Differentiation 27)CD40 (Cluster of differentiation 40 receptor)TLR4 (Toll-like receptor 4)TCR (T cell antigen receptor complex)CD40LG (CD40 ligand extracellular domain)CD70 (Cluster of Differentiation 70)GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on ECI-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECI-006.